Date: 2016-08-17
Type of information: Licensing agreement
Compound: MIV-802
Company: Medivir (Sweden) Trek Therapeutics (USA - MA)
Therapeutic area: Infectious diseases
Type agreement: licensing - development - commercialisation
Action mechanism:
- NS5B polymerase inhibitor/enzyme inhibitor/nucleotide analog. MIV-802 is a pangenotypic nucleotide-based inhibitor of the HCV NS5B polymerase. Preclinical data indicate that MIV-802 can be used effectively in combination with other classes of antiviral agents for the treatment of HCV, including protease inhibitors and NS5A inhibitors.
Disease: hepatitis C
Details:
- • On August 17, 2016, Medivir and Trek Therapeutics announced that TREKtx has licensed the exclusive rights to develop and commercialize MIV-802 globally, excluding China, Taiwan, Hong Kong and Macau. MIV-802 is a nucleotide polymerase inhibitor under development for the treatment of hepatitis C virus (HCV) infection. TREKtx is developing combination treatments for HCV utilizing its portfolio of antiviral agents including faldaprevir, a protease inhibitor, TD-6450, a NS5A inhibitor, and lomibuvir, a non-nucleoside NS5B inhibitor.
Financial terms:
- Under the terms of the agreement, Medivir is entitled to receive milestones based on successful clinical development and royalties capped at a mid-teens percentage upon commercialization of MIV-802 containing products. BioPhausia, a subsidiary of Medivir, is granted options to commercialize MIV-802 containing products in the Nordics and certain Western European countries. Other terms of the transaction were not disclosed.
Latest news:
Is general: Yes
